Search

A recent study conducted at Okayama University in Japan focused on a 55-year-old man with idiopathic pulmonary fibrosis who developed Mycobacterium avium pulmonary disease. Despite initial treatment, sputum conversion could not be achieved until the patient received amikacin liposome inhalation suspension (ALIS) therapy, leading to successful single-lung transplantation. The research suggests that ALIS may have potential benefits for treating M. avium pulmonary disease in patients requiring lung transplants. The study has been peer-reviewed and provides valuable insights into the use of liposomes in biotechnology and drug delivery systems. [Extracted from the article]

The patent application by Oliver Claude Venn focuses on methods for tracking genetic variants in cancer patients over time to create a tumor classification signature. This longitudinal tracking can help detect minimal residual disease, guide treatment decisions, and predict treatment resistance. By analyzing genetic diversity in tumors and patients, this method aims to improve treatment efficacy and generate targets for immune response. The patent application emphasizes the importance of tracking genetic variations in cancer patients to enhance diagnosis, treatment, and disease monitoring. [Extracted from the article]

A recent study conducted at the Third People's Hospital in China aims to evaluate the efficacy and safety of two different treatment durations for patients with drug-susceptible pulmonary tuberculosis (DS-PTB) and concurrent type 2 diabetes (DM). The study will compare a 6-month regimen to a 9-month regimen and assess outcomes such as treatment success rate, recurrence rates, and adverse events. The researchers hope that the study will provide valuable insights into the appropriate treatment duration for this vulnerable population and improve overall treatment outcomes. The trial is registered with Chictr.org.cn. [Extracted from the article]

This document provides information about a clinical trial conducted by Genentech, Inc. The trial, NCT06603246, aims to evaluate the safety and effectiveness of inhaled GDC-6988 in patients with muco-obstructive disease. The trial is set to begin on October 31, 2024, and is expected to be completed by January 15, 2026. The study will assess various outcomes, including adverse events, spirometry abnormalities, plasma concentration of GDC-6988, and changes in sputum percent solids and whole-lung mucociliary clearance. The intervention involves administering GDC-6988 through a dry powder inhaler. The trial is open to individuals with bronchiectasis and chronic obstructive pulmonary disease (COPD), and aims to enroll 128 participants. Eligibility criteria include specific lung function measurements and stable disease status. The document also provides administrative information, such as the study ID number and contact details for further inquiries. [Extracted from the article]

A patent application has been submitted for a method of detecting lung inflammation by measuring glucose levels in a sputum sample. The method aims to provide a quick and affordable way to detect lung inflammation, especially in cases of inflammatory diseases like COVID-19. The process involves measuring glucose levels using a spectrophotometer device and comparing them to predetermined thresholds to determine the presence of lung inflammation. The application also mentions the possibility of using a chest CT-scan assay for further detection and treating the inflammation with anti-inflammatory medications. [Extracted from the article]

A new report presents fresh data on tuberculosis research, specifically focusing on the performance of a targeted next-generation sequencing (tNGS) test for tuberculosis identification, genotyping, and detection of drug resistance mutations. The study evaluated the AmPORE TB assay, which has been approved by the World Health Organization (WHO) as a diagnostic test for TB. The assay demonstrated a high validity rate of 98% and achieved positive and negative agreements for detecting mutations associated with drug resistance. It also significantly reduced the time for reporting from days to hours compared to existing solutions. The study concludes that the AmPORE TB assay shows good performance, flexibility, and faster turnaround time for drug-resistant TB profiling. [Extracted from the article]

Researchers from Stellenbosch University have developed a novel aerosol collection device called PneumoniaCheck (PMC) that can capture airborne Mycobacterium tuberculosis (MTBC) and analyze the cough aeromicrobiome in individuals with tuberculosis (TB). The study found that PMC was able to detect MTBC in aerosols more effectively than in sputum samples using sequencing techniques. The aeromicrobiome in aerosols was found to be distinct from sputum, oral washes, and bronchoalveolar lavage fluid (BALF), and contained different types of lower respiratory tract microbes. This research provides valuable insights into the transmission and diagnosis of TB. [Extracted from the article]

Researchers from Maranatha Christian University in Bandung, Indonesia conducted a study on tuberculosis (TB) in the Purwakarta district, which has a high incidence of TB cases. The researchers carried out active case-finding activities in the Plered subdistrict, using a combination of registration, anamnesis, physical examination, sputum sampling, and chest x-ray examination with a mobile x-ray machine. Out of the 231 patients who underwent chest x-ray examination, 21 were diagnosed with TB. The study concluded that this approach can facilitate public access to health services and increase the rate of finding TB cases. [Extracted from the article]

A patent has been issued for a medical device and methods for detecting and monitoring tuberculosis. The device uses nanosensor technology to detect volatile organic compounds emitted by the skin, which indicate active tuberculosis. This skin-mountable device provides a fast and reliable diagnosis without the need for expensive equipment or specialized skills. It can also communicate with other devices or servers for more accurate evaluation and real-time monitoring. The patent provides detailed information about the device's components and materials used. [Extracted from the article]

The article focuses on a clinical trial evaluating the efficacy and safety of Cadonilimab (AK104) combined with chemotherapy and bevacizumab for first-line treatment in patients with RAS-mutated or right-sided metastatic MSS colorectal cancer. It explains that the study includes participants aged 18-75 who have measurable tumors and meet specific inclusion criteria, with the aim of determining the combined treatment's effectiveness and safety profile.

The article announces a Phase II clinical trial aimed at evaluating the efficacy and safety of ensifentrine inhalation for non-cystic fibrosis bronchiectasis. Topics discussed include the study's design (randomized, double-blind, placebo-controlled), primary and secondary outcomes (pulmonary exacerbations, symptom severity, and quality of life), and recruitment details.

The article reports on the initiation of a clinical trial, NCT06554145, aimed at developing an AI system to predict bacterial species from urine Gram stain images and assessing its accuracy and impact on labor reduction. Topics discussed include the trial's recruitment and timeline, the primary outcome measures related to AI concordance with culture results, and the involvement of institutions like Keio University and Kameda Medical Center.

A recent study conducted by the National Institute for Medical Research (NIMR) focused on the diagnosis of tuberculosis (TB) among people living with HIV (PLHIV) in Tanzania and Mozambique. The study aimed to assess the impact of an expanded screening strategy using multiple specimens (sputum, stool, and urine) for TB diagnosis among PLHIV admitted to hospitals. The intervention arm of the study utilized Xpert MTB/RIF Ultra(R) and urine LF-LAM testing, while the control arm followed the standard WHO recommendations. The primary endpoint of the study was the proportion of participants with microbiologically confirmed TB starting treatment within 3 days of enrollment. The researchers hope that this enhanced diagnostic strategy will help detect missed TB cases and be implemented on a larger scale. [Extracted from the article]

A recent study conducted by Hirosaki University in Japan focused on a 48-year-old man who presented with a fever and back pain. The patient was diagnosed with disseminated non-tuberculous mycobacteriosis, a condition characterized by bone destruction and abscess formation. The researchers found anti-interferon-gamma-neutralizing autoantibodies in the patient's serum, suggesting acquired immunodeficiency as the cause. While the lesions generally regressed with antimicrobial chemotherapy, the skull lesions worsened and required local resection for disease control. The patient is currently receiving drug therapy with good disease control after debridement. [Extracted from the article]

A recent study conducted in Liuzhou, People's Republic of China, explored the use of a gradient boosting decision tree (GBDT) in predicting postoperative atelectasis in patients with damaged lungs. The study included 170 patients who underwent surgical treatment at the Chest Hospital of Guangxi Zhuang Autonomous Region. The GBDT model identified operation time, intraoperative blood loss, presence of lung function, and sputum obstruction as the most influential factors in predicting atelectasis. The model's predictions closely matched the ideal curve and showed a higher net benefit than the reference line. The researchers concluded that the GBDT model is suitable for predicting complications in small samples. [Extracted from the article]

Toray Industries Inc. has been granted a patent for a kit, device, and method to detect lung cancer. The patent provides background information on lung cancer and its different tissue types. The inventors aim to identify a new tumor marker for lung cancer that can be used in initial tests and offer an effective method for detecting the disease using specific nucleic acids. The patent claims a method to detect and treat lung cancer by determining the expression level of hsa-miR-4730 in a sample from a human subject, such as blood, serum, or plasma. Treatment options include chemotherapy, radiotherapy, immunotherapy, molecular targeted therapy, surgery, or a combination of these. The patent also describes a method to detect lung cancer using specific nucleotide sequences, measuring the expression levels of certain microRNAs associated with the disease. The measurement can be done using quantitative RT-PCR or hybridization techniques. The patent also mentions other microRNAs that can be measured to determine the expression levels of additional lung cancer markers. Overall, this patent provides a kit, device, and method for detecting lung cancer. [Extracted from the article]

Researchers from the University of Pisa in Italy have conducted a study on the use of probiotics to combat persistent bacteria in cystic fibrosis (CF) patients. The study focused on the anti-persisters activity of culture filtrate supernatants of Lacticaseibacillus rhamnosus (LRM-CFS) against Pseudomonas aeruginosa, a common bacteria in CF patients. The researchers found that LRM-CFS showed bactericidal effects against P. aeruginosa persisters in an artificial sputum medium, as well as reducing antibiotic-tolerant bacteria in biofilms. This research suggests that LRM-CFS could be a promising adjuvant therapeutic strategy for CF patients with P. aeruginosa infections. [Extracted from the article]

This article discusses a clinical trial, NCT06505603, that focuses on studying lung density and biomarkers in PiMZ heterozygous patients with Alpha-1 Anti-trypsin Deficiency (AATD). The trial will use chest computed tomography (CT) scans to examine lung density and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in biomarkers. The goal is to develop biomarkers that can be used in interventional trials, as lung function changes do not typically inform disease progression in AATD. The trial is observational and will follow patients for three years. The study is led by Dr. Monica Goldklang from Columbia University and is being conducted in collaboration with the Alpha-1 Foundation. The data collected will be shared with the Alpha-1 Foundation Research Registry. [Extracted from the article]

This article discusses a clinical trial, NCT06459856, that is studying the effects of balloon blowing therapy and percussion on pulmonary functions in patients with pneumonia. The trial aims to improve lung function and clear mucus from the airways by using deep breathing exercises and percussion techniques. Participants will be divided into two groups and receive different interventions. The trial is currently recruiting participants in Pakistan and could potentially lead to a more comprehensive approach to pneumonia treatment. [Extracted from the article]

A study conducted by researchers at Charles University in Prague, Czech Republic, focused on a rare case of postoperative infection in a patient who underwent bilateral lung transplantation. The patient, who was immunosuppressed, developed an infection following sternum dislocation and wound dehiscence after recovering from a COVID-19 infection. The researchers identified the bacterium Metamycoplasma hominis in the patient's wound secretion, which was likely linked to colonization in the donor lungs. The infection was successfully treated with clindamycin, although the bacterium continued to be detected in the patient's sputum after treatment. This research has been peer-reviewed and published in Folia Microbiologica. [Extracted from the article]

This document provides information about a clinical trial called PRISM-TB, which aims to compare different treatment strategies for patients with fluoroquinolone-susceptible multidrug-resistant or rifampicin-resistant tuberculosis. The trial will evaluate the effectiveness of different drug regimens and their durations based on the latest World Health Organization guidelines and local standard of care. The study will recruit 690 participants and is estimated to be completed by November 2029. The trial is being conducted by the University of California, San Francisco in collaboration with Johns Hopkins University. [Extracted from the article]

A patent application for an aspirate-guiding apparatus and aspirate-suctioning system has been filed by inventor Naoyuki Ishikita. The apparatus is designed to guide aspirates, such as sputum, from the lower respiratory tract to the upper respiratory tract, making it easier to remove them from the body. The system includes a switching valve that can connect the patient to either a suction apparatus or an intake apparatus, allowing for easy suctioning of the aspirate. This invention aims to improve the process of removing aspirates from the respiratory tract, reducing the risk of damage to the respiratory system. [Extracted from the article]

A report from researchers at the University Hospital Southampton NHS Foundation Trust in the United Kingdom discusses the use of a non-invasive device called the particles in exhaled air (PExA) for assessing respiratory diseases. The PExA device captures particles from the distal airways and can count and measure their mass. These particles can be analyzed for lung-specific markers of inflammation, providing a more accurate understanding of pathophysiological changes in patients with lung diseases. The researchers suggest that PExA may be an alternative to traditional methods of airway sampling. [Extracted from the article]

A study conducted at Xinjiang Medical University in China investigated the impact of intraoperative infusion of recombinant human-activated coagulation factor VII (rFVIIa) on postoperative outcomes in patients with acute aortic dissection (AAD). The study involved 120 individuals who underwent aortic coarctation surgery. The participants were divided into control and study groups, with the study group receiving rFVIIa infusion in addition to conventional treatment. The study found that the study group had lower levels of chest drainage, required fewer blood transfusions, and had less postoperative mechanical ventilation compared to the control group. However, further studies with larger sample sizes are needed to comprehensively assess the clinical advantages and drawbacks of this treatment. [Extracted from the article]

A patent has been issued for a positioning sputum suction laryngeal mask developed by Wuxi Holy Noah Technology Co. Ltd. The mask aims to address the limitations of existing laryngeal masks by providing effective suction of secretions, avoiding airway blockage, and improving stability and reliability. The mask features a compact structure, lower complexity, and usage costs, and does not require air inflation for ventilation and sealing. It also includes a connection suction mechanism for negative pressure suction and multiple hollow regions for guiding secretions into a stomach decompression tube. The patent provides detailed descriptions and claims for the positioning sputum suction laryngeal mask. [Extracted from the article]

The Abramson Cancer Center at Penn Medicine is conducting a clinical trial, NCT06413355, to evaluate the use of Fibroblast Activating Protein (FAP) PET/CT in imaging fibrosis caused by various medical conditions. The trial aims to assess the presence of fibrosis and its effects on prognosis. Participants with fibrosis-inducing conditions such as cancer-associated, post-infection, post-radiation, pre or post-transplant, cardiac, liver, kidney, or pulmonary fibrosis will be included in the study. The trial will use [18F]-FAPI-74, a radiolabeled FAP inhibitor, with PET/CT scans to evaluate the distribution of FAP in affected organs and tissues. The results of the scans will not directly impact treatment decisions, which will be made by treating physicians based on clinical criteria. The trial is estimated to be completed by May 30, 2027. [Extracted from the article]

A patent has been issued for diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells. The invention provides a less invasive method for diagnosing lung diseases, such as lung cancer, based on gene expression analysis in nose epithelial cells. The gene expression changes in nose epithelial cells closely mirror the gene expression changes in lung epithelial cells, allowing for accurate diagnosis, prognosis, and follow-up of lung diseases. This method is non-invasive, does not require specialized equipment, and can be used for screening individuals at risk of developing lung diseases. [Extracted from the article]

A patent application has been filed for a biological specimen imaging unit that can be used inside an incubator. The unit includes an imager, receptacles for holding the biological specimen vessels, and processing circuitry. The imager generates images of the specimens, which are then processed to determine biological characteristics. The unit also includes a transceiver for transmitting the results to an interface device outside the incubator. The invention aims to provide a more user-friendly, reproducible, and cost-efficient technique for biological specimen incubation and analysis. [Extracted from the article]

A patent application has been submitted for an oral sampling device that can be used to collect saliva samples for disease diagnosis. The device is designed to be placed inside the mouth and has a recess on its outer surface to capture bodily fluids. The device can be used to capture various types of analytes and can be tailored for specific target analytes. It is made of a rigid porous material and may undergo surface treatments to enhance analyte capture. The device may also include a flavored substance to make sample collection more enjoyable and improve compliance, especially in children. The invention expands the range of diseases that can be detected from saliva samples and may be packaged and sold as a kit for disease diagnosis. [Extracted from the article]

A report from Westmead Hospital in Sydney, Australia, discusses the safe clinical use of sputum induction for bio-sampling of the lower airways in children and adults. Sputum induction is a common method used to collect biological samples, but it has been associated with serious adverse events, including deaths. The position statement, commissioned by the Thoracic Society of Australia and New Zealand, provides guidelines for the safe use of sputum induction, covering topics such as informed consent, infection control, and risk assessment. The research was conducted by a multidisciplinary group and has been peer-reviewed. [Extracted from the article]

Researchers from the University of Agriculture Faisalabad in Pakistan have conducted a study on the potential use of surface-enhanced Raman spectroscopy (SERS) for early diagnosis of tuberculosis (TB) based on blood serum. The study involved analyzing blood serum samples from TB patients using SERS and comparing them with healthy samples. The researchers found that SERS analysis of the filtrate portions of blood serum samples obtained through centrifugal filtration using 50 kDa devices could accurately differentiate TB samples from healthy samples. This research provides insights into the potential use of SERS for TB diagnosis. [Extracted from the article]

A patent has been issued to Abbott Molecular Inc. for compositions and methods for the detection and analysis of Mycobacterium tuberculosis (MTB). MTB is a serious threat to public health and is one of the top killers worldwide, second only to HIV/AIDS. The patent describes kits, reagents, and methods for nucleic acid amplification and detection procedures that specifically and sensitively detect MTB in samples such as sputum and bronchial alveolar lavage. These compositions and methods provide a low-cost, prompt, and accurate molecular test for MTB, which is important for the prevention and control of the disease. [Extracted from the article]

A new report discusses research findings on tuberculosis, specifically focusing on the effectiveness of Advocacy Communication and Social Mobilization (ACSM) intervention strategy through key community leaders. The study was conducted in Puducherry, India, and involved training leaders on TB to enhance awareness in the community. The research utilized the RE-AIM framework to evaluate the intervention's reach, effectiveness, adoption, implementation, and maintenance. The study found a marginal increase in the proportion of presumptive TB cases after the intervention, and a total of 77 presumptive TB cases were identified through community-based active case finding. The research concludes that involving leaders from diverse backgrounds optimizes the chance of success and emphasizes the importance of sustainability through initiatives like TB support groups. [Extracted from the article]

This document provides information about a Phase II clinical trial currently recruiting participants in China. The trial aims to evaluate the effectiveness and safety of cadonilimab in combination with pemetrexed and anlotinib for the treatment of elderly patients with advanced non-small cell lung cancer. The study plans to enroll 20 elderly patients and will involve several cycles of treatment followed by maintenance treatment. Regular imaging assessments will be conducted, and the trial is expected to be completed by December 2024. The trial is led by Haibo Zhang from Guangzhou University of Traditional Chinese Medicine. [Extracted from the article]

Toray Industries Inc. has been granted a patent for a lung cancer detection kit and method. The patent provides background information on lung cancer, its prevalence, and stages of progression. The inventors claim that their method, which involves measuring the expression level of hsa-miR-3162-5p in a blood sample, can accurately detect lung cancer. The device used for measurement includes nucleic acids that specifically bind to hsa-miR-3162-5p, as well as other lung cancer markers. This technology has potential applications in oncology and could aid in the early detection of lung cancer. [Extracted from the article]

Researchers from the Institute for Biomedical Engineering in Hsinchu, Taiwan have developed a new method for detecting cancer cells in sputum samples. The researchers focused on improving the efficiency and accuracy of sputum smears, which are commonly used for detecting cancer in the lower respiratory tract. They developed a vertical bubble acoustic microfluidic sputum liquefier that can mix sputum and lysis buffer in a harmless and efficient manner, allowing for easier concentration of cancer cells. The researchers expect that this device will increase the positive rate of pathological examination of sputum smears in patients with lung cancer in the future. [Extracted from the article]

Researchers from the University of Lampung have developed an early detection information system for risk factors that may delay sputum conversion in tuberculosis (TB) patients. The system, supported by an expert system, aims to identify risk factors such as low social determinants, presence of co-morbidities, and medication nonadherence. By providing immediate detection and expert recommendations, the system increases the chances of sputum conversion in the first two months of TB treatment. This research contributes to the improvement of TB control programs and treatment outcomes. [Extracted from the article]

A study conducted by J.N. Medical College in Belagavi district, North Karnataka, India, analyzed the factors that influence the successful treatment outcome of tuberculosis (TB) patients. The study found that females, younger age groups, absence of comorbidities, patients with extra-pulmonary TB, smear-negative pulmonary TB, and new TB patients had a statistically significant association with successful treatment outcomes. The study also highlighted the importance of early detection and comprehensive counseling for TB patients in achieving successful treatment outcomes. The mean treatment success rate in the study area aligned with the national success rate. [Extracted from the article]

E.F.A. Engineering for All Ltd. has been issued a patent for a portable digital diagnostic device. The device aims to bring microscopy and electrochemistry tests to remote areas for on-site testing with instant results. It is a handheld device that can be used by minimally trained operators, such as community health workers, and can be coupled with a mobile device for analysis and diagnosis. The device has the potential to provide rapid and accurate diagnoses, allowing for immediate treatment and prevention of the spread of diseases. [Extracted from the article]

A patent has been issued for a sputum collection and washing apparatus and a method of using it. The invention aims to improve the reliability of clinical diagnostic testing for respiratory infections by optimizing the self-collection, transport, decontamination, sampling, and storage preservation of sputum specimens. The apparatus includes a transparent container with a mesh assembly and a removable lid, while the method involves collecting the sputum specimen, filling the container with a wash fluid, agitating the sample, and draining the fluid. The invention aims to empower pathogen-specific antibiotic stewardship and improve laboratory support for treatment decisions. [Extracted from the article]

However, it brings about early closure of cavities and decreases inflammation in the lungs secondary to tuberculosis and, thus, may favor faster recovery and decreased lung tissue damage." Keywords: Tamil Nadu; India; Asia; Actinomycetales Infections; Antidiabetic Agents; Biguanides; Biomarkers; Clinical Research; Clinical Trials and Studies; Diagnostics and Screening; Drugs and Therapies; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Health and Medicine; Hypoglycemic Agents; Inflammation; Lung Diseases and Conditions; Metformin; Metformin Therapy; Mycobacterium Infections; Mycobacterium Tuberculosis; Non-Sulfonylureas; Pharmaceuticals; Pulmonary Tuberculosis; Tuberculosis EN Tamil Nadu India Asia Actinomycetales Infections Antidiabetic Agents Biguanides Biomarkers Clinical Research Clinical Trials and Studies Diagnostics and Screening Drugs and Therapies Gram-Positive Bacteria Gram-Positive Bacterial Infections Health and Medicine Hypoglycemic Agents Inflammation Lung Diseases and Conditions Metformin Metformin Therapy Mycobacterium Infections Mycobacterium Tuberculosis Non-Sulfonylureas Pharmaceuticals Pulmonary Tuberculosis Tuberculosis 1257 1257 1 10/30/23 20231103 NES 231103 2023 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at TB & Outbreaks Week -- A new study on Lung Diseases and Conditions - Pulmonary Tuberculosis is now available. [Extracted from the article]

Recently, it has been shown that combinations of antibiotics (for example, mixtures of two or more antibiotics) can be more potent than using individual drugs, enabling the use of lower doses and the treatment of otherwise drug resistant bacteria. Existing drug susceptibility platforms that work at the single-cell level generally are destructive or require labels, such that the same cell cannot be interrogated multiple times with distinct drugs, drug combinations, or varying drug concentrations. Keywords: Antibacterials; Antibiotics; Antimicrobials; Biomarkers; Cancer; Diagnostics and Screening; Drugs and Therapies; Emerging Technologies; Health and Medicine; Metastatic Cancer; Nanorods; Nanotechnology; Oncology; Patent Application EN Antibacterials Antibiotics Antimicrobials Biomarkers Cancer Diagnostics and Screening Drugs and Therapies Emerging Technologies Health and Medicine Metastatic Cancer Nanorods Nanotechnology Oncology Patent Application 683 683 1 10/30/23 20231030 NES 231030 2023 NOV 2 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Vaccine Week -- A patent application by the inventors Dionne, Jennifer A (Menlo Park, CA, US); HU, Jack (Stanford, CA, US); Jeffrey, Stefanie S. (Los Altos Hills, CA, US); Saleh, Amr Ahmed Essawi (Palo Alto, CA, US); Tadesse, Loza Fekadu (Los Altos Hills, CA, US), filed on September 1, 2021, was made available online on October 12, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. "Drug development, drug repurposing, and drug use in clinical trials. [Extracted from the article]

Keywords: Asthma; Biomarkers; Bronchial Diseases and Conditions; Cancer; Chronic Obstructive Pulmonary Disease; Diagnosis; Diagnostics and Screening; Health and Medicine; Immune System Diseases and Conditions; Lung Cancer; Lung Diseases and Conditions; Lung Neoplasms; Obstructive Lung Diseases and Conditions; Oncology; Respiratory Hypersensitivity; Respiratory Tract Diseases and Conditions; Sputum Induction EN Asthma Biomarkers Bronchial Diseases and Conditions Cancer Chronic Obstructive Pulmonary Disease Diagnosis Diagnostics and Screening Health and Medicine Immune System Diseases and Conditions Lung Cancer Lung Diseases and Conditions Lung Neoplasms Obstructive Lung Diseases and Conditions Oncology Respiratory Hypersensitivity Respiratory Tract Diseases and Conditions Sputum Induction 1243 1243 1 10/30/23 20231030 NES 231030 2023 OCT 31 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- New research on chronic obstructive pulmonary disease is the subject of a new report. Asthma, Biomarkers, Bronchial Diseases and Conditions, Cancer, Chronic Obstructive Pulmonary Disease, Diagnosis, Diagnostics and Screening, Health and Medicine, Immune System Diseases and Conditions, Lung Cancer, Lung Diseases and Conditions, Lung Neoplasms, Obstructive Lung Diseases and Conditions, Oncology, Respiratory Hypersensitivity, Respiratory Tract Diseases and Conditions, Sputum Induction. [Extracted from the article]

The apparatus of claim 1, wherein the second port is joined with the junction so that the housing is less than 75 mm away from an intubation tube axis of the intubation tube, whereby the accumulated liquid accumulates in the housing rather than in the intubation tube. The apparatus of claim 1, wherein the second port is joined with the junction so that the housing is less than 50 mm away from an intubation tube axis of the intubation tube. The suction catheter can be disposed in the sleeve and can be reciprocally movable through the connection end to apply a first suction to accumulated liquids in the intubation tube and/or the patient's airway and lungs. [Extracted from the article]

Mtb DNA from the matrix was released into a DNA-release buffer and detected using a WHO-approved CB-NAAT detection platform. Actinomycetales Infections, Gram-Positive Bacteria, Health and Medicine, Mycobacterium Infections, Mycobacterium Infections - Tuberculosis, Mycobacterium Tuberculosis, Tuberculosis WITHDRAWN: Estimating limit of detection of M. tuberculosis DNA as an analyte released from a chemically coated solid matrix and using a WHO-approved CB-NAAT platform. [Extracted from the article]

After receiving 8 weeks of treatment, participants randomised to the TBAJ876-Pa-L treatment arms will receive open-label HR for at least 7 weeks. After receiving 8 weeks of trial treatment, all participants randomised to the HRZE arm will receive open-label HR for 18 weeks, for a total of 26 weeks of treatment. [Extracted from the article]

Asthma Control Test measures the adequacy of asthma control and change in asthma control which may occur spontaneously or in response to treatment. Keywords: Acid Reflux Disease; Aeroallergens; Allergies; Allergy Research; Asthma; Bronchial Diseases and Conditions; Bronchoscopy; Chemicals; Clinical Research; Clinical Trials and Studies; Diagnostics and Screening; Digestive System Diseases and Conditions; Digestive System Diseases and Conditions - Acid Reflux Disease; Genetics; Genomics; Health and Medicine; Immune System Diseases and Conditions; Lung Diseases and Conditions; Nitric Oxide; Nitrogen Oxides; Obstructive Lung Diseases and Conditions; Pharmaceuticals; RNA Research; Reactive Nitrogen Species; Respiratory Hypersensitivity; Respiratory Tract Diseases and Conditions; Surgical Procedures EN Acid Reflux Disease Aeroallergens Allergies Allergy Research Asthma Bronchial Diseases and Conditions Bronchoscopy Chemicals Clinical Research Clinical Trials and Studies Diagnostics and Screening Digestive System Diseases and Conditions Digestive System Diseases and Conditions - Acid Reflux Disease Genetics Genomics Health and Medicine Immune System Diseases and Conditions Lung Diseases and Conditions Nitric Oxide Nitrogen Oxides Obstructive Lung Diseases and Conditions Pharmaceuticals RNA Research Reactive Nitrogen Species Respiratory Hypersensitivity Respiratory Tract Diseases and Conditions Surgical Procedures 1776 1776 1 09/25/23 20230929 NES 230929 2023 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Imaging Week -- Staff editors report on the newly launched clinical trial, NCT06028204, which has the following summary description: "The goal of this observational study is to investigate the role of the lung microbiome in patients with asthma and how it may influence the response to asthma specific treatments. [Extracted from the article]

Keywords: Haikou; People's Republic of China; Asia; Experimental Biology; Life Sciences; Health and Medicine; Quality of Life EN Haikou People's Republic of China Asia Experimental Biology Life Sciences Health and Medicine Quality of Life 3477 3477 1 09/11/23 20230915 NES 230915 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on Life Sciences - Experimental Biology is now available. In this study, we evaluated the effects of nursing intervention combined with respiratory muscle assessment-based muscle relaxation training on postoperative pulmonary function rehabilitation, sputum excretion and quality of life in patients receiving thoracic surgeries.". [Extracted from the article]

Rapid diagnostic testing devices produce a visible band on a rapid diagnostic testing device by binding an antigen (e.g., TB-LAM) using antibodies, such as dye-labeled antibodies. Multiple new diagnostic tests have recently been developed for detecting active tuberculosis, latent tuberculosis infection, and identifying drug-resistant strains of Mycobacterial tuberculosis. Rapid diagnostic testing devices employ rapid diagnostic tests that are medical diagnostic tests that are quick and easy to perform and can be carried out even in the absence of laboratory techniques such as microscopy, enzyme-linked immunosorbent assay (ELISA) or polymerase chain reaction (PCR). [Extracted from the article]